Saturday, April 28, 2012

FDA approves Vivus's fast-acting Viagra rival

NEW YORK (Reuters) -

Men with erectile dysfunction may not have to plan for sex as far in advance anymore after Vivus Inc won U.S. approval for avanafil, its faster acting rival to Viagra.

Avanafil, which will be sold under the brand name Stendra, is the first new drug in the category in a decade.

While it is recommended that patients take the new pill 30 minutes prior to sexual activity, in clinical trials it has been shown to work in as fast as 15 minutes. Viagra typically takes about an hour to start working.

The most common side effects reported in clinical studies included headache, flushing of the face and other areas, nasal congestion, common cold-like symptoms and back pain.

Read the full Reuters Health report:   
 FDA approves Vivus's fast-acting Viagra rival